USE OF PROSTAGLANDIN (PGE2) RECEPTOR 4 (EP4) SELECTIVE AGONIST FOR TREATMENT OF ACUTE AND CHRONIC RENAL FAILURE

PROBLEM TO BE SOLVED: To provide a medicinal composition of treating acute or chronic renal disease such as renal failure or dysfunction. SOLUTION: The composition contains an EP 4 receptor selective prostaglandin (PGE2) agonist, especially a pyrrolidone derivative such as 5-(3-hydroxy-4-phenyl-but-...

Full description

Saved in:
Bibliographic Details
Main Authors PARALKAR VISHWAS MADHAV, THOMPSON DAVID DUANE
Format Patent
LanguageEnglish
Published 13.07.2006
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:PROBLEM TO BE SOLVED: To provide a medicinal composition of treating acute or chronic renal disease such as renal failure or dysfunction. SOLUTION: The composition contains an EP 4 receptor selective prostaglandin (PGE2) agonist, especially a pyrrolidone derivative such as 5-(3-hydroxy-4-phenyl-but-1-enyl)-1-[6-(1H-tetrazol-5-yl)-hexyl]-pyrrolidin-2-one, 5-(3-hydroxy-4-phenyl-butyl)-1-[6-(1H-tetrazol-5-yl)-hexyl]-pyrrolidin-2-one and 7-[2-(3-hydroxy-4-phenyl-but-1-enyl)-5-oxo-pyrrolidin-1-yl]-heptanoic acid. COPYRIGHT: (C)2006,JPO&NCIPI
Bibliography:Application Number: JP20060047746